Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS
Coya Therapeutics plans to initiate an open-label extension of the Phase 2/3 ALSTARS trial of COYA 302 in ALS, beginning in November 2026, letting participants who complete 48 weeks continue treatment. Concurrent with the OLE, Coya is prioritizing resources on the ALS program, pushing the planned Phase 2 trial of COYA 302 in frontotemporal dementia from the second half of 2026 into 2027.
Key figures
- Drug Name
- COYA 302
- Phase Of Trial
- Phase 2/3
- Ole start
- November 2026
- Cash runway
- into the second half of 2027
- Topline readout
- early Q2 2027
- Alstars subjects
- 120
- Ftd trial timing
- delayed from H2 2026 to 2027
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.